nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—lung cancer	0.188	1	CrCtD
Epirubicin—Topoisomerase Inhibitors—Teniposide—lung cancer	0.0702	0.23	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Topotecan—lung cancer	0.0626	0.205	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Irinotecan—lung cancer	0.0532	0.174	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—lung cancer	0.0509	0.167	CiPCiCtD
Epirubicin—thyroid cancer—lung cancer	0.0463	0.26	CtDrD
Epirubicin—liver cancer—lung cancer	0.0447	0.251	CtDrD
Epirubicin—Topoisomerase Inhibitors—Etoposide—lung cancer	0.0418	0.137	CiPCiCtD
Epirubicin—Valrubicin—Doxorubicin—lung cancer	0.0395	0.333	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—lung cancer	0.0395	0.333	CrCrCtD
Epirubicin—Daunorubicin—Doxorubicin—lung cancer	0.0395	0.333	CrCrCtD
Epirubicin—AURKA—Crizotinib—lung cancer	0.0368	0.283	CbGbCtD
Epirubicin—bone cancer—lung cancer	0.0343	0.193	CtDrD
Epirubicin—testicular cancer—lung cancer	0.0285	0.16	CtDrD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—lung cancer	0.0266	0.0871	CiPCiCtD
Epirubicin—sarcoma—lung cancer	0.0242	0.136	CtDrD
Epirubicin—AURKA—Doxorubicin—lung cancer	0.0175	0.135	CbGbCtD
Epirubicin—DHCR7—Doxorubicin—lung cancer	0.0175	0.135	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—lung cancer	0.0175	0.135	CbGbCtD
Epirubicin—TOP2A—Teniposide—lung cancer	0.0118	0.0911	CbGbCtD
Epirubicin—TOP2A—Etoposide—lung cancer	0.00522	0.0402	CbGbCtD
Epirubicin—ABCC1—Paclitaxel—lung cancer	0.00366	0.0282	CbGbCtD
Epirubicin—ABCC1—Irinotecan—lung cancer	0.00361	0.0278	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—lung cancer	0.00356	0.0274	CbGbCtD
Epirubicin—ABCC1—Vinblastine—lung cancer	0.00321	0.0247	CbGbCtD
Epirubicin—ABCC1—Etoposide—lung cancer	0.00289	0.0223	CbGbCtD
Epirubicin—ABCC1—Docetaxel—lung cancer	0.00265	0.0204	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—lung cancer	0.00197	0.0152	CbGbCtD
Epirubicin—ABCC1—Methotrexate—lung cancer	0.00191	0.0147	CbGbCtD
Epirubicin—CHD1—mammary gland—lung cancer	0.000881	0.076	CbGeAlD
Epirubicin—AURKA—mammary gland—lung cancer	0.00071	0.0613	CbGeAlD
Epirubicin—DHCR7—mammary gland—lung cancer	0.000594	0.0513	CbGeAlD
Epirubicin—CHD1—respiratory system—lung cancer	0.000587	0.0507	CbGeAlD
Epirubicin—YWHAG—mammary gland—lung cancer	0.000545	0.047	CbGeAlD
Epirubicin—CHD1—bronchus—lung cancer	0.000483	0.0417	CbGeAlD
Epirubicin—CHD1—trachea—lung cancer	0.000434	0.0374	CbGeAlD
Epirubicin—CHD1—cardiac atrium—lung cancer	0.000408	0.0352	CbGeAlD
Epirubicin—YWHAG—respiratory system—lung cancer	0.000363	0.0313	CbGeAlD
Epirubicin—CHD1—bone marrow—lung cancer	0.000344	0.0297	CbGeAlD
Epirubicin—DHCR7—bronchus—lung cancer	0.000326	0.0281	CbGeAlD
Epirubicin—CHD1—lung—lung cancer	0.000312	0.0269	CbGeAlD
Epirubicin—YWHAG—bronchus—lung cancer	0.000299	0.0258	CbGeAlD
Epirubicin—DHCR7—trachea—lung cancer	0.000293	0.0252	CbGeAlD
Epirubicin—AURKA—bone marrow—lung cancer	0.000277	0.0239	CbGeAlD
Epirubicin—DHCR7—cardiac atrium—lung cancer	0.000275	0.0237	CbGeAlD
Epirubicin—PLA2G4A—respiratory system—lung cancer	0.000271	0.0234	CbGeAlD
Epirubicin—YWHAG—trachea—lung cancer	0.000269	0.0232	CbGeAlD
Epirubicin—YWHAG—cardiac atrium—lung cancer	0.000252	0.0218	CbGeAlD
Epirubicin—AURKA—lung—lung cancer	0.000251	0.0217	CbGeAlD
Epirubicin—DHCR7—bone marrow—lung cancer	0.000232	0.02	CbGeAlD
Epirubicin—PLA2G4A—bronchus—lung cancer	0.000223	0.0192	CbGeAlD
Epirubicin—CHD1—lymph node—lung cancer	0.000213	0.0184	CbGeAlD
Epirubicin—YWHAG—bone marrow—lung cancer	0.000213	0.0184	CbGeAlD
Epirubicin—TOP2A—bronchus—lung cancer	0.000212	0.0183	CbGeAlD
Epirubicin—DHCR7—lung—lung cancer	0.00021	0.0181	CbGeAlD
Epirubicin—PLA2G4A—trachea—lung cancer	0.0002	0.0173	CbGeAlD
Epirubicin—YWHAG—lung—lung cancer	0.000193	0.0166	CbGeAlD
Epirubicin—AURKA—lymph node—lung cancer	0.000172	0.0148	CbGeAlD
Epirubicin—CHD1—Topotecan—Irinotecan—lung cancer	0.000162	0.173	CbGdCrCtD
Epirubicin—Doxorubicin—NQO1—lung cancer	0.000162	0.253	CrCbGaD
Epirubicin—Doxorubicin—ABCC3—lung cancer	0.000159	0.249	CrCbGaD
Epirubicin—PLA2G4A—bone marrow—lung cancer	0.000159	0.0137	CbGeAlD
Epirubicin—TOP2A—bone marrow—lung cancer	0.000151	0.013	CbGeAlD
Epirubicin—PLA2G4A—lung—lung cancer	0.000144	0.0124	CbGeAlD
Epirubicin—DHCR7—lymph node—lung cancer	0.000144	0.0124	CbGeAlD
Epirubicin—TOP2A—lung—lung cancer	0.000137	0.0118	CbGeAlD
Epirubicin—YWHAG—lymph node—lung cancer	0.000132	0.0114	CbGeAlD
Epirubicin—ABCC1—bronchus—lung cancer	0.000128	0.011	CbGeAlD
Epirubicin—ABCC1—trachea—lung cancer	0.000115	0.00988	CbGeAlD
Epirubicin—PLA2G4A—Raltitrexed—Pemetrexed—lung cancer	0.00011	0.117	CbGdCrCtD
Epirubicin—ABCC1—cardiac atrium—lung cancer	0.000108	0.00928	CbGeAlD
Epirubicin—PLA2G4A—lymph node—lung cancer	9.84e-05	0.00849	CbGeAlD
Epirubicin—Daunorubicin—ABCG2—lung cancer	9.51e-05	0.149	CrCbGaD
Epirubicin—TOP2A—lymph node—lung cancer	9.35e-05	0.00807	CbGeAlD
Epirubicin—ABCC1—lung—lung cancer	8.23e-05	0.0071	CbGeAlD
Epirubicin—Doxorubicin—ABCG2—lung cancer	7.72e-05	0.121	CrCbGaD
Epirubicin—Daunorubicin—CYP1A1—lung cancer	7.45e-05	0.117	CrCbGaD
Epirubicin—AURKA—Irinotecan—Topotecan—lung cancer	6.42e-05	0.0685	CbGdCrCtD
Epirubicin—ABCC1—lymph node—lung cancer	5.63e-05	0.00486	CbGeAlD
Epirubicin—AURKA—Topotecan—Irinotecan—lung cancer	5.34e-05	0.057	CbGdCrCtD
Epirubicin—AURKA—Etoposide—Teniposide—lung cancer	5.3e-05	0.0566	CbGdCrCtD
Epirubicin—Daunorubicin—ABCB1—lung cancer	3.96e-05	0.062	CrCbGaD
Epirubicin—AURKA—Methotrexate—Pemetrexed—lung cancer	3.81e-05	0.0406	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—lung cancer	3.53e-05	0.0377	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—lung cancer	3.53e-05	0.0377	CbGdCrCtD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—lung cancer	3.39e-05	0.0361	CbGdCrCtD
Epirubicin—Doxorubicin—ABCB1—lung cancer	3.21e-05	0.0503	CrCbGaD
Epirubicin—TOP2A—Docetaxel—Paclitaxel—lung cancer	2.87e-05	0.0306	CbGdCrCtD
Epirubicin—TOP2A—Irinotecan—Topotecan—lung cancer	2.45e-05	0.0262	CbGdCrCtD
Epirubicin—AURKA—Teniposide—Etoposide—lung cancer	2.4e-05	0.0257	CbGdCrCtD
Epirubicin—TOP2A—Erlotinib—Gefitinib—lung cancer	2.14e-05	0.0228	CbGdCrCtD
Epirubicin—TOP2A—Topotecan—Irinotecan—lung cancer	2.04e-05	0.0218	CbGdCrCtD
Epirubicin—TOP2A—Etoposide—Teniposide—lung cancer	2.03e-05	0.0216	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vinorelbine—lung cancer	1.82e-05	0.0195	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Teniposide—lung cancer	1.54e-05	0.0165	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vinblastine—lung cancer	1.46e-05	0.0156	CbGdCrCtD
Epirubicin—TOP2A—Methotrexate—Pemetrexed—lung cancer	1.45e-05	0.0155	CbGdCrCtD
Epirubicin—TOP2A—Paclitaxel—Docetaxel—lung cancer	1.43e-05	0.0153	CbGdCrCtD
Epirubicin—TOP2A—Afatinib—Gefitinib—lung cancer	1.4e-05	0.0149	CbGdCrCtD
Epirubicin—TOP2A—Gefitinib—Erlotinib—lung cancer	1.37e-05	0.0147	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Gemcitabine—lung cancer	1.35e-05	0.0144	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—lung cancer	1.16e-05	0.0124	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—lung cancer	1.16e-05	0.0124	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinorelbine—lung cancer	9.83e-06	0.0105	CbGdCrCtD
Epirubicin—TOP2A—Vinorelbine—Vinblastine—lung cancer	9.2e-06	0.00982	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—lung cancer	9.19e-06	0.00981	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Etoposide—lung cancer	9.19e-06	0.00981	CbGdCrCtD
Epirubicin—TOP2A—Vinblastine—Vinorelbine—lung cancer	7.91e-06	0.00844	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinblastine—lung cancer	7.86e-06	0.00839	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Gemcitabine—lung cancer	5.17e-06	0.00552	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—lung cancer	4.43e-06	0.00473	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—lung cancer	4.43e-06	0.00473	CbGdCrCtD
Epirubicin—Diarrhoea—Irinotecan—lung cancer	4.34e-06	9.34e-05	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—lung cancer	4.32e-06	9.28e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Etoposide—lung cancer	4.32e-06	9.28e-05	CcSEcCtD
Epirubicin—Shock—Docetaxel—lung cancer	4.32e-06	9.28e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Docetaxel—lung cancer	4.3e-06	9.25e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Docetaxel—lung cancer	4.3e-06	9.24e-05	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—lung cancer	4.29e-06	9.23e-05	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—lung cancer	4.29e-06	9.23e-05	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—lung cancer	4.29e-06	9.23e-05	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—lung cancer	4.29e-06	9.22e-05	CcSEcCtD
Epirubicin—Tachycardia—Docetaxel—lung cancer	4.28e-06	9.21e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Paclitaxel—lung cancer	4.27e-06	9.17e-05	CcSEcCtD
Epirubicin—Skin disorder—Docetaxel—lung cancer	4.26e-06	9.16e-05	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—lung cancer	4.26e-06	9.15e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Cisplatin—lung cancer	4.25e-06	9.13e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Paclitaxel—lung cancer	4.23e-06	9.1e-05	CcSEcCtD
Epirubicin—Diarrhoea—Gemcitabine—lung cancer	4.23e-06	9.09e-05	CcSEcCtD
Epirubicin—Renal failure—Doxorubicin—lung cancer	4.22e-06	9.07e-05	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—lung cancer	4.21e-06	9.05e-05	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—lung cancer	4.21e-06	9.05e-05	CcSEcCtD
Epirubicin—Dizziness—Irinotecan—lung cancer	4.2e-06	9.02e-05	CcSEcCtD
Epirubicin—Urticaria—Etoposide—lung cancer	4.19e-06	9.02e-05	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—lung cancer	4.19e-06	9e-05	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—lung cancer	4.19e-06	9e-05	CcSEcCtD
Epirubicin—Anorexia—Docetaxel—lung cancer	4.18e-06	8.99e-05	CcSEcCtD
Epirubicin—Abdominal pain—Etoposide—lung cancer	4.17e-06	8.97e-05	CcSEcCtD
Epirubicin—Body temperature increased—Etoposide—lung cancer	4.17e-06	8.97e-05	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—lung cancer	4.17e-06	8.97e-05	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—lung cancer	4.17e-06	8.97e-05	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—lung cancer	4.16e-06	8.94e-05	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—lung cancer	4.15e-06	8.92e-05	CcSEcCtD
Epirubicin—Asthenia—Cisplatin—lung cancer	4.14e-06	8.89e-05	CcSEcCtD
Epirubicin—Cardiac disorder—Methotrexate—lung cancer	4.13e-06	8.88e-05	CcSEcCtD
Epirubicin—Sweating—Doxorubicin—lung cancer	4.12e-06	8.85e-05	CcSEcCtD
Epirubicin—Urticaria—Paclitaxel—lung cancer	4.11e-06	8.84e-05	CcSEcCtD
Epirubicin—Hypotension—Docetaxel—lung cancer	4.1e-06	8.81e-05	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—lung cancer	4.09e-06	8.8e-05	CcSEcCtD
Epirubicin—Abdominal pain—Paclitaxel—lung cancer	4.09e-06	8.8e-05	CcSEcCtD
Epirubicin—Body temperature increased—Paclitaxel—lung cancer	4.09e-06	8.8e-05	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—lung cancer	4.06e-06	8.73e-05	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—lung cancer	4.05e-06	8.71e-05	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—lung cancer	4.04e-06	8.68e-05	CcSEcCtD
Epirubicin—Vomiting—Irinotecan—lung cancer	4.04e-06	8.68e-05	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—lung cancer	4.03e-06	8.66e-05	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—lung cancer	4.02e-06	8.64e-05	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—lung cancer	4.01e-06	8.62e-05	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—lung cancer	4.01e-06	8.61e-05	CcSEcCtD
Epirubicin—Rash—Irinotecan—lung cancer	4e-06	8.6e-05	CcSEcCtD
Epirubicin—Dermatitis—Irinotecan—lung cancer	4e-06	8.6e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Docetaxel—lung cancer	4e-06	8.59e-05	CcSEcCtD
Epirubicin—Chills—Methotrexate—lung cancer	3.99e-06	8.59e-05	CcSEcCtD
Epirubicin—Headache—Irinotecan—lung cancer	3.98e-06	8.55e-05	CcSEcCtD
Epirubicin—Insomnia—Docetaxel—lung cancer	3.97e-06	8.53e-05	CcSEcCtD
Epirubicin—Diarrhoea—Cisplatin—lung cancer	3.94e-06	8.48e-05	CcSEcCtD
Epirubicin—Paraesthesia—Docetaxel—lung cancer	3.94e-06	8.47e-05	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—lung cancer	3.93e-06	8.46e-05	CcSEcCtD
Epirubicin—Vomiting—Gemcitabine—lung cancer	3.93e-06	8.45e-05	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—lung cancer	3.92e-06	8.44e-05	CcSEcCtD
Epirubicin—Dyspnoea—Docetaxel—lung cancer	3.91e-06	8.41e-05	CcSEcCtD
Epirubicin—Somnolence—Docetaxel—lung cancer	3.9e-06	8.39e-05	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—lung cancer	3.9e-06	8.38e-05	CcSEcCtD
Epirubicin—Rash—Gemcitabine—lung cancer	3.9e-06	8.38e-05	CcSEcCtD
Epirubicin—Dermatitis—Gemcitabine—lung cancer	3.9e-06	8.37e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Etoposide—lung cancer	3.89e-06	8.36e-05	CcSEcCtD
Epirubicin—Erythema—Methotrexate—lung cancer	3.88e-06	8.33e-05	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—lung cancer	3.88e-06	8.33e-05	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—lung cancer	3.87e-06	8.33e-05	CcSEcCtD
Epirubicin—Headache—Gemcitabine—lung cancer	3.87e-06	8.33e-05	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—lung cancer	3.86e-06	8.31e-05	CcSEcCtD
Epirubicin—Dyspepsia—Docetaxel—lung cancer	3.86e-06	8.3e-05	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—lung cancer	3.85e-06	8.29e-05	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—lung cancer	3.85e-06	8.29e-05	CcSEcCtD
Epirubicin—Hypoaesthesia—Doxorubicin—lung cancer	3.84e-06	8.24e-05	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—lung cancer	3.83e-06	8.22e-05	CcSEcCtD
Epirubicin—Decreased appetite—Docetaxel—lung cancer	3.81e-06	8.2e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Paclitaxel—lung cancer	3.81e-06	8.2e-05	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—lung cancer	3.81e-06	8.18e-05	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—lung cancer	3.8e-06	8.16e-05	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—lung cancer	3.79e-06	8.16e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Docetaxel—lung cancer	3.79e-06	8.14e-05	CcSEcCtD
Epirubicin—Asthenia—Etoposide—lung cancer	3.79e-06	8.14e-05	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—lung cancer	3.79e-06	8.14e-05	CcSEcCtD
Epirubicin—Fatigue—Docetaxel—lung cancer	3.78e-06	8.13e-05	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—lung cancer	3.78e-06	8.12e-05	CcSEcCtD
Epirubicin—Nausea—Irinotecan—lung cancer	3.77e-06	8.11e-05	CcSEcCtD
Epirubicin—Pain—Docetaxel—lung cancer	3.75e-06	8.07e-05	CcSEcCtD
Epirubicin—Constipation—Docetaxel—lung cancer	3.75e-06	8.07e-05	CcSEcCtD
Epirubicin—Back pain—Methotrexate—lung cancer	3.75e-06	8.06e-05	CcSEcCtD
Epirubicin—Pruritus—Etoposide—lung cancer	3.74e-06	8.03e-05	CcSEcCtD
Epirubicin—Visual impairment—Doxorubicin—lung cancer	3.71e-06	7.99e-05	CcSEcCtD
Epirubicin—Asthenia—Paclitaxel—lung cancer	3.71e-06	7.98e-05	CcSEcCtD
Epirubicin—TOP2A—Azacitidine—Gemcitabine—lung cancer	3.7e-06	0.00395	CbGdCrCtD
Epirubicin—Nausea—Gemcitabine—lung cancer	3.67e-06	7.9e-05	CcSEcCtD
Epirubicin—Vomiting—Cisplatin—lung cancer	3.66e-06	7.88e-05	CcSEcCtD
Epirubicin—Pruritus—Paclitaxel—lung cancer	3.66e-06	7.87e-05	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—lung cancer	3.65e-06	7.85e-05	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—lung cancer	3.64e-06	7.83e-05	CcSEcCtD
Epirubicin—Rash—Cisplatin—lung cancer	3.63e-06	7.81e-05	CcSEcCtD
Epirubicin—Dermatitis—Cisplatin—lung cancer	3.63e-06	7.8e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Docetaxel—lung cancer	3.62e-06	7.77e-05	CcSEcCtD
Epirubicin—Diarrhoea—Etoposide—lung cancer	3.61e-06	7.77e-05	CcSEcCtD
Epirubicin—Eye disorder—Doxorubicin—lung cancer	3.6e-06	7.74e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—lung cancer	3.6e-06	7.73e-05	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—lung cancer	3.59e-06	7.73e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Docetaxel—lung cancer	3.59e-06	7.71e-05	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—lung cancer	3.58e-06	7.7e-05	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—lung cancer	3.58e-06	7.69e-05	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—lung cancer	3.58e-06	7.69e-05	CcSEcCtD
Epirubicin—Diarrhoea—Paclitaxel—lung cancer	3.54e-06	7.61e-05	CcSEcCtD
Epirubicin—Angiopathy—Doxorubicin—lung cancer	3.5e-06	7.52e-05	CcSEcCtD
Epirubicin—Malaise—Methotrexate—lung cancer	3.49e-06	7.51e-05	CcSEcCtD
Epirubicin—Dizziness—Etoposide—lung cancer	3.49e-06	7.51e-05	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—lung cancer	3.48e-06	7.48e-05	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—lung cancer	3.48e-06	7.48e-05	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—lung cancer	3.47e-06	7.47e-05	CcSEcCtD
Epirubicin—Abdominal pain—Docetaxel—lung cancer	3.47e-06	7.46e-05	CcSEcCtD
Epirubicin—Body temperature increased—Docetaxel—lung cancer	3.47e-06	7.46e-05	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—lung cancer	3.47e-06	7.46e-05	CcSEcCtD
Epirubicin—Chills—Doxorubicin—lung cancer	3.46e-06	7.44e-05	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—lung cancer	3.44e-06	7.4e-05	CcSEcCtD
Epirubicin—Dizziness—Paclitaxel—lung cancer	3.42e-06	7.36e-05	CcSEcCtD
Epirubicin—Nausea—Cisplatin—lung cancer	3.42e-06	7.36e-05	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—lung cancer	3.41e-06	7.32e-05	CcSEcCtD
Epirubicin—Cough—Methotrexate—lung cancer	3.38e-06	7.27e-05	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—lung cancer	3.38e-06	7.26e-05	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—lung cancer	3.36e-06	7.22e-05	CcSEcCtD
Epirubicin—Vomiting—Etoposide—lung cancer	3.36e-06	7.22e-05	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—lung cancer	3.36e-06	7.21e-05	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—lung cancer	3.36e-06	7.21e-05	CcSEcCtD
Epirubicin—Rash—Etoposide—lung cancer	3.33e-06	7.16e-05	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—lung cancer	3.33e-06	7.15e-05	CcSEcCtD
Epirubicin—Headache—Etoposide—lung cancer	3.31e-06	7.11e-05	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—lung cancer	3.31e-06	7.11e-05	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—lung cancer	3.3e-06	7.09e-05	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—lung cancer	3.3e-06	7.09e-05	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—lung cancer	3.3e-06	7.09e-05	CcSEcCtD
Epirubicin—Tension—Doxorubicin—lung cancer	3.29e-06	7.08e-05	CcSEcCtD
Epirubicin—Vomiting—Paclitaxel—lung cancer	3.29e-06	7.08e-05	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—lung cancer	3.29e-06	7.06e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.28e-06	7.04e-05	CcSEcCtD
Epirubicin—Rash—Paclitaxel—lung cancer	3.26e-06	7.02e-05	CcSEcCtD
Epirubicin—Dermatitis—Paclitaxel—lung cancer	3.26e-06	7.01e-05	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—lung cancer	3.26e-06	7.01e-05	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—lung cancer	3.26e-06	7.01e-05	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—lung cancer	3.25e-06	6.98e-05	CcSEcCtD
Epirubicin—Headache—Paclitaxel—lung cancer	3.24e-06	6.97e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Docetaxel—lung cancer	3.23e-06	6.95e-05	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—lung cancer	3.23e-06	6.94e-05	CcSEcCtD
Epirubicin—Confusional state—Methotrexate—lung cancer	3.19e-06	6.86e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—lung cancer	3.16e-06	6.8e-05	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—lung cancer	3.16e-06	6.8e-05	CcSEcCtD
Epirubicin—Asthenia—Docetaxel—lung cancer	3.15e-06	6.77e-05	CcSEcCtD
Epirubicin—Infection—Methotrexate—lung cancer	3.14e-06	6.75e-05	CcSEcCtD
Epirubicin—Nausea—Etoposide—lung cancer	3.14e-06	6.74e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—lung cancer	3.11e-06	6.69e-05	CcSEcCtD
Epirubicin—Pruritus—Docetaxel—lung cancer	3.1e-06	6.67e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—lung cancer	3.1e-06	6.67e-05	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—lung cancer	3.1e-06	6.67e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—lung cancer	3.1e-06	6.66e-05	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—lung cancer	3.08e-06	6.63e-05	CcSEcCtD
Epirubicin—Nausea—Paclitaxel—lung cancer	3.08e-06	6.61e-05	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—lung cancer	3.07e-06	6.6e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—lung cancer	3.06e-06	6.57e-05	CcSEcCtD
Epirubicin—Malaise—Doxorubicin—lung cancer	3.03e-06	6.51e-05	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—lung cancer	3.01e-06	6.48e-05	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—lung cancer	3.01e-06	6.48e-05	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—lung cancer	3.01e-06	6.47e-05	CcSEcCtD
Epirubicin—Leukopenia—Doxorubicin—lung cancer	3e-06	6.46e-05	CcSEcCtD
Epirubicin—Diarrhoea—Docetaxel—lung cancer	3e-06	6.45e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—AVP—lung cancer	2.99e-06	0.000144	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ENO1—lung cancer	2.98e-06	0.000143	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—lung cancer	2.97e-06	6.37e-05	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—lung cancer	2.96e-06	6.35e-05	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—lung cancer	2.95e-06	6.34e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDKN1A—lung cancer	2.94e-06	0.000141	CbGpPWpGaD
Epirubicin—Cough—Doxorubicin—lung cancer	2.93e-06	6.29e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—ENO1—lung cancer	2.92e-06	0.00014	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GNG11—lung cancer	2.91e-06	0.00014	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.91e-06	0.00014	CbGpPWpGaD
Epirubicin—Convulsion—Doxorubicin—lung cancer	2.91e-06	6.25e-05	CcSEcCtD
Epirubicin—Dizziness—Docetaxel—lung cancer	2.9e-06	6.24e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFC—lung cancer	2.9e-06	0.000139	CbGpPWpGaD
Epirubicin—Hypertension—Doxorubicin—lung cancer	2.9e-06	6.23e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—APOA1—lung cancer	2.9e-06	0.000139	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PTEN—lung cancer	2.88e-06	0.000139	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Methotrexate—lung cancer	2.88e-06	6.19e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.87e-06	0.000138	CbGpPWpGaD
Epirubicin—Insomnia—Methotrexate—lung cancer	2.86e-06	6.15e-05	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—lung cancer	2.86e-06	6.14e-05	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—lung cancer	2.86e-06	6.14e-05	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—lung cancer	2.86e-06	6.14e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—RAF1—lung cancer	2.85e-06	0.000137	CbGpPWpGaD
Epirubicin—Anxiety—Doxorubicin—lung cancer	2.85e-06	6.12e-05	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—lung cancer	2.84e-06	6.11e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.84e-06	6.1e-05	CcSEcCtD
Epirubicin—Discomfort—Doxorubicin—lung cancer	2.82e-06	6.07e-05	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—lung cancer	2.82e-06	6.06e-05	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—lung cancer	2.81e-06	6.04e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—EP300—lung cancer	2.8e-06	0.000134	CbGpPWpGaD
Epirubicin—Dry mouth—Doxorubicin—lung cancer	2.79e-06	6.01e-05	CcSEcCtD
Epirubicin—Vomiting—Docetaxel—lung cancer	2.79e-06	6e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—ENO1—lung cancer	2.79e-06	0.000134	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CB—lung cancer	2.79e-06	0.000134	CbGpPWpGaD
Epirubicin—Dyspepsia—Methotrexate—lung cancer	2.78e-06	5.98e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—ALDOA—lung cancer	2.77e-06	0.000133	CbGpPWpGaD
Epirubicin—Rash—Docetaxel—lung cancer	2.77e-06	5.95e-05	CcSEcCtD
Epirubicin—Dermatitis—Docetaxel—lung cancer	2.76e-06	5.94e-05	CcSEcCtD
Epirubicin—Confusional state—Doxorubicin—lung cancer	2.76e-06	5.94e-05	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—APOA1—lung cancer	2.75e-06	0.000132	CbGpPWpGaD
Epirubicin—Decreased appetite—Methotrexate—lung cancer	2.75e-06	5.91e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—EP300—lung cancer	2.75e-06	0.000132	CbGpPWpGaD
Epirubicin—Headache—Docetaxel—lung cancer	2.75e-06	5.91e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—ADCY1—lung cancer	2.74e-06	0.000132	CbGpPWpGaD
Epirubicin—Anaphylactic shock—Doxorubicin—lung cancer	2.74e-06	5.89e-05	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—lung cancer	2.74e-06	5.89e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—lung cancer	2.73e-06	5.87e-05	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—lung cancer	2.73e-06	5.86e-05	CcSEcCtD
Epirubicin—Infection—Doxorubicin—lung cancer	2.72e-06	5.85e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CCND1—lung cancer	2.72e-06	0.000131	CbGpPWpGaD
Epirubicin—Pain—Methotrexate—lung cancer	2.7e-06	5.81e-05	CcSEcCtD
Epirubicin—Shock—Doxorubicin—lung cancer	2.69e-06	5.79e-05	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—lung cancer	2.69e-06	0.000129	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOA3—lung cancer	2.69e-06	0.000129	CbGpPWpGaD
Epirubicin—Nervous system disorder—Doxorubicin—lung cancer	2.69e-06	5.77e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—lung cancer	2.68e-06	5.76e-05	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—lung cancer	2.67e-06	5.75e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CYP2E1—lung cancer	2.67e-06	0.000128	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PPP2R1B—lung cancer	2.67e-06	0.000128	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMARCA4—lung cancer	2.67e-06	0.000128	CbGpPWpGaD
Epirubicin—Skin disorder—Doxorubicin—lung cancer	2.66e-06	5.72e-05	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—lung cancer	2.65e-06	5.69e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	2.64e-06	0.000127	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NQO1—lung cancer	2.64e-06	0.000127	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—CDKN1A—lung cancer	2.63e-06	0.000126	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP2E1—lung cancer	2.62e-06	0.000126	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ABCG2—lung cancer	2.62e-06	0.000126	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ADCY1—lung cancer	2.62e-06	0.000126	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—lung cancer	2.61e-06	5.61e-05	CcSEcCtD
Epirubicin—Nausea—Docetaxel—lung cancer	2.61e-06	5.6e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Methotrexate—lung cancer	2.61e-06	5.6e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—APP—lung cancer	2.59e-06	0.000125	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NQO1—lung cancer	2.59e-06	0.000125	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Methotrexate—lung cancer	2.59e-06	5.56e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—HSPB1—lung cancer	2.58e-06	0.000124	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FGF9—lung cancer	2.57e-06	0.000124	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—HPGDS—lung cancer	2.57e-06	0.000123	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ENO2—lung cancer	2.57e-06	0.000123	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—lung cancer	2.56e-06	5.5e-05	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TP53—lung cancer	2.56e-06	0.000123	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—IL2—lung cancer	2.56e-06	0.000123	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PPP2R1B—lung cancer	2.55e-06	0.000123	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTHLH—lung cancer	2.55e-06	0.000122	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.54e-06	0.000122	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—POMC—lung cancer	2.52e-06	0.000121	CbGpPWpGaD
Epirubicin—Urticaria—Methotrexate—lung cancer	2.51e-06	5.4e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.51e-06	0.000121	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—lung cancer	2.51e-06	0.00012	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—EP300—lung cancer	2.5e-06	0.00012	CbGpPWpGaD
Epirubicin—Body temperature increased—Methotrexate—lung cancer	2.5e-06	5.37e-05	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—lung cancer	2.5e-06	5.37e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—lung cancer	2.5e-06	5.36e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GSTT1—lung cancer	2.49e-06	0.00012	CbGpPWpGaD
Epirubicin—Insomnia—Doxorubicin—lung cancer	2.48e-06	5.32e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP2A6—lung cancer	2.46e-06	0.000118	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GCLC—lung cancer	2.46e-06	0.000118	CbGpPWpGaD
Epirubicin—Paraesthesia—Doxorubicin—lung cancer	2.46e-06	5.29e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—JUNB—lung cancer	2.45e-06	0.000118	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	2.45e-06	0.000118	CbGpPWpGaD
Epirubicin—Dyspnoea—Doxorubicin—lung cancer	2.44e-06	5.25e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—lung cancer	2.44e-06	0.000117	CbGpPWpGaD
Epirubicin—Somnolence—Doxorubicin—lung cancer	2.43e-06	5.23e-05	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—lung cancer	2.41e-06	5.18e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—ANXA1—lung cancer	2.39e-06	0.000115	CbGpPWpGaD
Epirubicin—Decreased appetite—Doxorubicin—lung cancer	2.38e-06	5.12e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—STK11—lung cancer	2.38e-06	0.000114	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Doxorubicin—lung cancer	2.36e-06	5.08e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—lung cancer	2.36e-06	5.08e-05	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—lung cancer	2.34e-06	5.03e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—lung cancer	2.34e-06	5.03e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—STK11—lung cancer	2.33e-06	0.000112	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ENO1—lung cancer	2.33e-06	0.000112	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—CREBBP—lung cancer	2.33e-06	0.000112	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—lung cancer	2.33e-06	5.01e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	2.32e-06	0.000112	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FLT1—lung cancer	2.32e-06	0.000112	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—EP300—lung cancer	2.3e-06	0.00011	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—ALB—lung cancer	2.29e-06	0.00011	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH3—lung cancer	2.27e-06	0.000109	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APP—lung cancer	2.27e-06	0.000109	CbGpPWpGaD
Epirubicin—Asthenia—Methotrexate—lung cancer	2.27e-06	4.88e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Doxorubicin—lung cancer	2.26e-06	4.85e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FGF9—lung cancer	2.25e-06	0.000108	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MAPK3—lung cancer	2.24e-06	0.000108	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Doxorubicin—lung cancer	2.24e-06	4.81e-05	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—lung cancer	2.24e-06	4.81e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—SRC—lung cancer	2.23e-06	0.000107	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTP1—lung cancer	2.2e-06	0.000106	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—lung cancer	2.19e-06	0.000105	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ALB—lung cancer	2.18e-06	0.000105	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—lung cancer	2.18e-06	0.000105	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—lung cancer	2.18e-06	4.68e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—lung cancer	2.17e-06	0.000105	CbGpPWpGaD
Epirubicin—Abdominal pain—Doxorubicin—lung cancer	2.16e-06	4.65e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—lung cancer	2.16e-06	4.65e-05	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—lung cancer	2.16e-06	4.65e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GSTP1—lung cancer	2.16e-06	0.000104	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUNB—lung cancer	2.15e-06	0.000103	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FOXO3—lung cancer	2.15e-06	0.000103	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—NRAS—lung cancer	2.15e-06	0.000103	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CAT—lung cancer	2.14e-06	0.000103	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CAT—lung cancer	2.1e-06	0.000101	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP2E1—lung cancer	2.09e-06	0.000101	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—lung cancer	2.09e-06	4.5e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.09e-06	0.0001	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CG—lung cancer	2.09e-06	0.0001	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ABCB1—lung cancer	2.08e-06	0.0001	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NQO1—lung cancer	2.07e-06	9.95e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—MAPK3—lung cancer	2.06e-06	9.89e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TYMS—lung cancer	2.05e-06	9.85e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ABCB1—lung cancer	2.04e-06	9.83e-05	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—PIK3CA—lung cancer	2.03e-06	9.78e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	2.03e-06	9.74e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTM1—lung cancer	2.02e-06	9.73e-05	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—lung cancer	2.02e-06	4.34e-05	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—lung cancer	2.01e-06	4.32e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—TYMS—lung cancer	2.01e-06	9.66e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	2.01e-06	9.65e-05	CbGpPWpGaD
Epirubicin—Rash—Methotrexate—lung cancer	1.99e-06	4.29e-05	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—lung cancer	1.99e-06	4.28e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—POMC—lung cancer	1.99e-06	9.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTM1—lung cancer	1.98e-06	9.54e-05	CbGpPWpGaD
Epirubicin—Headache—Methotrexate—lung cancer	1.98e-06	4.26e-05	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—RAF1—lung cancer	1.97e-06	9.49e-05	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—lung cancer	1.96e-06	4.22e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—STK11—lung cancer	1.95e-06	9.39e-05	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—lung cancer	1.94e-06	4.17e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6R—lung cancer	1.94e-06	9.32e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYP1A1—lung cancer	1.92e-06	9.23e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HES1—lung cancer	1.9e-06	9.16e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ERCC2—lung cancer	1.9e-06	9.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FOXO3—lung cancer	1.88e-06	9.06e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP1A1—lung cancer	1.88e-06	9.05e-05	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—lung cancer	1.88e-06	4.04e-05	CcSEcCtD
Epirubicin—Diarrhoea—Doxorubicin—lung cancer	1.87e-06	4.03e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—ERCC2—lung cancer	1.87e-06	8.97e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—STK11—lung cancer	1.87e-06	8.97e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—KRAS—lung cancer	1.85e-06	8.89e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAP2K1—lung cancer	1.85e-06	8.88e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CD—lung cancer	1.83e-06	8.82e-05	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—lung cancer	1.81e-06	3.89e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—lung cancer	1.79e-06	8.61e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERCC2—lung cancer	1.78e-06	8.56e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AVP—lung cancer	1.77e-06	8.49e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.75e-06	8.42e-05	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—lung cancer	1.74e-06	3.74e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—ERBB3—lung cancer	1.74e-06	8.37e-05	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—lung cancer	1.73e-06	3.71e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GSTP1—lung cancer	1.73e-06	8.3e-05	CbGpPWpGaD
Epirubicin—Dermatitis—Doxorubicin—lung cancer	1.73e-06	3.71e-05	CcSEcCtD
Epirubicin—Headache—Doxorubicin—lung cancer	1.72e-06	3.69e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1R—lung cancer	1.7e-06	8.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—lung cancer	1.7e-06	8.17e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CAT—lung cancer	1.68e-06	8.08e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.67e-06	8.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HES1—lung cancer	1.67e-06	8.03e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—lung cancer	1.67e-06	8.03e-05	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AKT1—lung cancer	1.66e-06	7.99e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—APOA1—lung cancer	1.65e-06	7.92e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—lung cancer	1.64e-06	7.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—RAF1—lung cancer	1.64e-06	7.87e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ABCB1—lung cancer	1.63e-06	7.86e-05	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—lung cancer	1.63e-06	3.5e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—FGFR1—lung cancer	1.62e-06	7.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—APOA1—lung cancer	1.61e-06	7.76e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TYMS—lung cancer	1.6e-06	7.72e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CB—lung cancer	1.6e-06	7.69e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HIF1A—lung cancer	1.6e-06	7.68e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTM1—lung cancer	1.59e-06	7.63e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—lung cancer	1.57e-06	7.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.55e-06	7.43e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APOA1—lung cancer	1.54e-06	7.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL8—lung cancer	1.54e-06	7.39e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB3—lung cancer	1.53e-06	7.34e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CYP1A1—lung cancer	1.5e-06	7.23e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CG—lung cancer	1.5e-06	7.23e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ERCC2—lung cancer	1.49e-06	7.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CG—lung cancer	1.47e-06	7.09e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—lung cancer	1.47e-06	7.06e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—lung cancer	1.46e-06	7.03e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—POMC—lung cancer	1.43e-06	6.88e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR1—lung cancer	1.42e-06	6.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KIT—lung cancer	1.41e-06	6.76e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—APC—lung cancer	1.41e-06	6.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—POMC—lung cancer	1.4e-06	6.75e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HIF1A—lung cancer	1.4e-06	6.73e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CREBBP—lung cancer	1.39e-06	6.7e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGF—lung cancer	1.39e-06	6.68e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—lung cancer	1.39e-06	6.67e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CREBBP—lung cancer	1.37e-06	6.57e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APOA1—lung cancer	1.35e-06	6.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KDR—lung cancer	1.34e-06	6.43e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BRAF—lung cancer	1.32e-06	6.36e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CD—lung cancer	1.32e-06	6.35e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6R—lung cancer	1.31e-06	6.28e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ALB—lung cancer	1.3e-06	6.27e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CREBBP—lung cancer	1.3e-06	6.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CD—lung cancer	1.3e-06	6.23e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—APOA1—lung cancer	1.29e-06	6.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ALB—lung cancer	1.28e-06	6.15e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAP2K1—lung cancer	1.24e-06	5.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CD—lung cancer	1.24e-06	5.94e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	1.24e-06	5.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CG—lung cancer	1.23e-06	5.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIT—lung cancer	1.23e-06	5.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—APC—lung cancer	1.23e-06	5.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—lung cancer	1.23e-06	5.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGF—lung cancer	1.22e-06	5.86e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAPK3—lung cancer	1.18e-06	5.68e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CG—lung cancer	1.18e-06	5.66e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—POMC—lung cancer	1.17e-06	5.64e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BRAF—lung cancer	1.16e-06	5.57e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CB—lung cancer	1.15e-06	5.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6R—lung cancer	1.14e-06	5.5e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CREBBP—lung cancer	1.14e-06	5.49e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—lung cancer	1.14e-06	5.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CB—lung cancer	1.13e-06	5.43e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—lung cancer	1.12e-06	5.4e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—POMC—lung cancer	1.12e-06	5.39e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—lung cancer	1.12e-06	5.38e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MDM2—lung cancer	1.11e-06	5.33e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—RAF1—lung cancer	1.1e-06	5.31e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CREBBP—lung cancer	1.09e-06	5.25e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—ERBB2—lung cancer	1.09e-06	5.25e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAP2K1—lung cancer	1.09e-06	5.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CD—lung cancer	1.08e-06	5.21e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTOR—lung cancer	1.08e-06	5.18e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CB—lung cancer	1.08e-06	5.18e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD4—lung cancer	1.08e-06	5.17e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—lung cancer	1.07e-06	5.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—lung cancer	1.06e-06	5.1e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CD—lung cancer	1.04e-06	4.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ALB—lung cancer	1.02e-06	4.91e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—lung cancer	9.95e-07	4.79e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—lung cancer	9.76e-07	4.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—lung cancer	9.74e-07	4.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—lung cancer	9.7e-07	4.67e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RAF1—lung cancer	9.67e-07	4.65e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ERBB2—lung cancer	9.57e-07	4.6e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—EP300—lung cancer	9.49e-07	4.56e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CB—lung cancer	9.44e-07	4.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MTOR—lung cancer	9.44e-07	4.54e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1A—lung cancer	9.33e-07	4.49e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—lung cancer	9.31e-07	4.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—EP300—lung cancer	9.31e-07	4.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL8—lung cancer	9.07e-07	4.36e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CB—lung cancer	9.02e-07	4.34e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—lung cancer	9.02e-07	4.34e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—lung cancer	8.94e-07	4.3e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EP300—lung cancer	8.88e-07	4.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—lung cancer	8.68e-07	4.18e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—lung cancer	8.67e-07	4.17e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—lung cancer	8.63e-07	4.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—lung cancer	8.63e-07	4.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—lung cancer	8.45e-07	4.07e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUN—lung cancer	8.44e-07	4.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—lung cancer	8.33e-07	4e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—lung cancer	8.31e-07	3.99e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—lung cancer	8.21e-07	3.95e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1A—lung cancer	8.18e-07	3.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—lung cancer	8.16e-07	3.92e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—lung cancer	7.96e-07	3.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAPK3—lung cancer	7.95e-07	3.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—lung cancer	7.8e-07	3.75e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EP300—lung cancer	7.78e-07	3.74e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—lung cancer	7.74e-07	3.72e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—lung cancer	7.57e-07	3.64e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—lung cancer	7.57e-07	3.64e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—EP300—lung cancer	7.44e-07	3.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—lung cancer	7.37e-07	3.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—lung cancer	7.3e-07	3.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—lung cancer	7.28e-07	3.5e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—lung cancer	7.15e-07	3.44e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—lung cancer	7.02e-07	3.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK3—lung cancer	6.97e-07	3.35e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—lung cancer	6.88e-07	3.31e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—lung cancer	6.78e-07	3.26e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—lung cancer	6.63e-07	3.19e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—lung cancer	6.57e-07	3.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—lung cancer	6.27e-07	3.01e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—lung cancer	6.08e-07	2.92e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—lung cancer	5.82e-07	2.8e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—lung cancer	5.76e-07	2.77e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—lung cancer	5.73e-07	2.76e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—lung cancer	5.62e-07	2.7e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—lung cancer	5.57e-07	2.68e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—lung cancer	5.5e-07	2.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—lung cancer	5.37e-07	2.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—lung cancer	5.33e-07	2.56e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—lung cancer	5.1e-07	2.45e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—lung cancer	4.7e-07	2.26e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—lung cancer	4.49e-07	2.16e-05	CbGpPWpGaD
